Enkorten (metenkefalin/tridecactide) / Bosnalijek - LARVOL DELTA

A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS (clinicaltrials.gov) - P3 | N=301 | Terminated | Sponsor: Bosnalijek D.D | Recruiting ➔ Terminated; During the Covid-19 pandemic, the study was unable to enrol further patients.

Trial termination • CNS Disorders • Multiple Sclerosis

A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS (clinicaltrials.gov) - P3 | N=400 | Recruiting | Sponsor: Bosnalijek D.D | Trial completion date: Mar 2023 ➔ Jul 2024 | Trial primary completion date: Mar 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date • CNS Disorders • Multiple Sclerosis

Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection (clinicaltrials.gov) - P2/3; N=120; Completed; Sponsor: Bosnalijek D.D; Active, not recruiting ➔ Completed

Clinical • Trial completion • Immune Modulation • Infectious Disease • Inflammation • Novel Coronavirus Disease

Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection (clinicaltrials.gov) - P2/3; N=120; Active, not recruiting; Sponsor: Bosnalijek D.D; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Immune Modulation • Infectious Disease • Inflammation • Novel Coronavirus Disease